SAT102. Exploring Selective Sodium Channel Inhibition for the Management of Acute Pain (Non-CME) (ASA 2026) - Sep 29, 2026 - Pres time: Oct 17, 2026; 10:30 AM - 11:30 AM; Location: 3, Upper Level; "In this session we will explore the role of NaV1.8 in pain signaling, suzetrigine's mechanism of action, and findings from our clinical studies evaluating suzetrigine. Supported by Vertex Pharmaceuticals Incorporated"
Pain • NAV1
|